Clinical Trial Update: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) [Phase 3]

View source ↗

Summary

A Phase 3 trial (LEPRE) is evaluating letrozole for estrogen/progesterone receptor-positive low-grade serous epithelial ovarian cancer and is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Low-grade Serous Ovarian Cancer

Drugs mentioned

• Letrozole (letrozole)

Snippet

Sponsor: Ente Ospedaliero Ospedali Galliera | Conditions: Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary | Phase 3 | Status: RECRUITING